Zoledronic acid - Hospira
Latest Information Update: 20 Oct 2021
Price :
$50 *
At a glance
- Originator Hospira
- Class Antineoplastics; Bisphosphonates; Calcium regulators; Imidazoles; Osteoporosis therapies; Small molecules
- Mechanism of Action Bone resorption factor inhibitors; Geranylgeranyltransferase inhibitors; Osteoclast inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Bone metastases; Malignant hypercalcaemia; Multiple myeloma; Prostate cancer
Most Recent Events
- 08 Jul 2019 Chemical structure information added
- 04 Dec 2018 Zoledronic acid is not yet available in USA for Bone metastases, Malignant hypercalcaemia, Multiple myeloma and Prostate cancer indications (Hospira website, November 2018)
- 03 Sep 2015 Hospira has been acquired by Pfizer